ArticleActa pharmacologica Sinica2026
Chloroethylnitrosourea analogue HJ03 overcomes temozolomide resistance of glioblastoma in mice through induction of ferroptosis and apoptosis.
Article in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Surgery followed by adjuvant chemoradiation is the standard treatment for glioblastoma multiforme (GBM). Temozolomide (TMZ) is the only first-line chemotherapeutic drug approved by the US Food and Drug Administration for the treatment of GBM. Acquired chemoresistance to TMZ is the primary cause of treatment failure, resulting in recurrence and a poor prognosis. O6-methylguanine DNA methyltransferase (MGMT) overexpression and loss of function mutations targeting mismatch repair (MMR) are the major mechanisms TMZ-resistance found in GBM cells. In this study we developed a new alkylating agent that could overcome TMZ resistance. We designed a new chloroethylnitrosourea analog HJ03, and demonstrated that HJ03 was more potent than TMZ in inhibiting GBM cell lines U251 (MGMT
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.